Asset profile
HB0017
Monoclonal antibody
Evidence outlook · registrational
Psoriasis: registrational readout pending
Entered Phase 3 on partial signal mid-stage evidence. The registry's posted readout date (2024-08) has passed without a status update. Check News for topline announcements.
NCT05531682: The study was randomized and quadruple-blind, included a placebo control, and enrolled 160 participants; its primary endpoints were PASI 90 and sPGA 0/1 responses at week 12, which are clinical psoriasis outcomes. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Conference-abstract-only source (BJD 2024). The abstract reports the 300 mg vs placebo comparison (n=81); the registry lists 160 enrolled across dosing regimens.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
62 competitors in this universe: 2 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 26 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| HB0017: this drug | Phase 3 | Monoclonal antibody | IL-17A | ||
| ZL-1102 | Phase 2 | Monoclonal antibody | IL-17A | ||
| UA026 | Phase 1 | Small molecule | IL-17A | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | ||
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | ||
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F | ||
| Brepocitinib (Lisraya) | Approved | Small molecule | TYK2/JAK1 | ||
| Brodalumab (Siliq) | Approved | Monoclonal antibody | IL-17 receptor A | ||
| Calcipotriene / Betamethasone Dipropionate Cream (Wynzora) | Approved | Small molecule | Vitamin D receptor + Glucocorticoid receptor | ||
| Calcipotriene / Betamethasone Dipropionate Foam (Enstilar) | Approved | Small molecule | Vitamin D receptor + Glucocorticoid receptor | ||
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | ||
| Desoximetasone (Topicort Spray) | Approved | Small molecule | Glucocorticoid receptor agonist | ||
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | ||
| Etanercept (Enbrel) | Approved | Protein / enzyme therapeutic | TNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha) | ||
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Halobetasol Propionate Foam (Lexette) | Approved | Small molecule | Glucocorticoid receptor |
…and 47 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.